Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer

Molecular Carcinogenesis

Volumn 44, Issue 2, 2005, Pages 146-150

  Marsit, Carmen J ^a   Okpukpara, Chinedu ^a   Danaee, Hadi ^a   Kelsey, Karl T ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Lung cancer; Methylation; Trypsinogen

Indexed keywords

BIOLOGICAL MARKER; PROTEIN PRSS3; SERINE PROTEINASE; TRYPSINOGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CLINICAL FEATURE; DEMOGRAPHY; DIAGNOSTIC VALUE; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PRSS3 GENE; TOBACCO DEPENDENCE; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); SMOKING; TRYPSIN; TRYPSINOGEN;

NICOTIANA TABACUM;

EID: 25844464823     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20125     Document Type: Article

References (31)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
3. Bird A. The essentials of DNA methylation. Cell 1992;70: 5-8.
4. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-191.
5. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997;88:471-481.
6. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-389.
7. Minn A, Schubert M, Neiss WF, Muller-Hill B. Enhanced GFAP expression in astrocytes of transgenic mice expressing the human brain-specific trypsinogen IV. Glia 1998;22:338-347.
8. Tani T, Kawashima I, Mita K, Takiguchi Y. Nucleotide sequence of the human pancreatic trypsinogen III cDNA. Nucleic Acids Res 1990;18:1631.
9. Williams SJ, Gotley DC, Antalis TM. Human trypsinogen in colorectal cancer. Int J Cancer 2001;93:67-73.
10. Oyama K, Ohta T, Nishimura GI, et al. Trypsinogen expression in colorectal cancers. Int J Mol Med 2000;6:543-548.
11. Ohta T, Terada T, Nagakawa T, et al. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer 1994;69:152-156.
12. Miyata S, Koshikawa N, Higashi S, et al. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture, J Biochem (Tokyo) 1999;125:1067-1076.
13. Hirahara F, Miyagi Y, Miyagi E, et al. Trypsinogen expression in human ovarian carcinomas. Int J Cancer 1995;63:176-181.
14. Cottrell GS, Amadesi S, Grady EF, Bunnett NW. Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 2004;279:13532-13539.
15. Koshikawa N, Hasegawa S, Nagashima Y, et al. Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol 1998;153:937-944.
16. Lee M, Fridman R, Mobashery S. Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 2004;33:401-409.
17. Yamashita K, Mimori K, Inoue H, Mori M, Sidransky D. A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 2003;63:6575-6578.
18. Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996;56:3371-3379.
19. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-3424.
20. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-160.
21. Marsit CJ, Kim DH, Liu M, et al. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: Implications for tobacco smoking during adolescence. Int J Cancer 2005;114:219-223.
22. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999;91:2032-2038.
23. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93: 9821-9826.
24. Turker MS, Bestor TH. Formation of methylation patterns in the mammalian genome. Mutat Res 1997;386:119-130.
25. Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene 2002;21:5388-5393.
26. Sun FL, Elgin SC. Putting boundaries on silence. Cell 1999;99: 459-462.
27. Diederichs S, Bulk E, Steffen B, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 2004;64:5564-5569.
28. Li B, Goyal J, Dhar S, et al. CpG methylation as a basis for breast tumor-specific loss of NESI/kallikrein 10 expression. Cancer Res 2001;61:8014-8021.
29. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004;104:2492-2498.
30. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998;58:4782-4786.
31. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59:67-70.